EE200000595A - Toimeaine viimine kandjamaatriksisse - Google Patents

Toimeaine viimine kandjamaatriksisse

Info

Publication number
EE200000595A
EE200000595A EEP200000595A EEP200000595A EE200000595A EE 200000595 A EE200000595 A EE 200000595A EE P200000595 A EEP200000595 A EE P200000595A EE P200000595 A EEP200000595 A EE P200000595A EE 200000595 A EE200000595 A EE 200000595A
Authority
EE
Estonia
Prior art keywords
delivery
active ingredient
carrier matrix
matrix
carrier
Prior art date
Application number
EEP200000595A
Other languages
English (en)
Estonian (et)
Inventor
Andersson Marie-Louise
Boissier Catherine
Marie Juppo Anne
Larsson Anette
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200000595A publication Critical patent/EE200000595A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Nozzles (AREA)
EEP200000595A 1998-04-14 1999-04-09 Toimeaine viimine kandjamaatriksisse EE200000595A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801287A SE9801287D0 (sv) 1998-04-14 1998-04-14 Incorporation of active substances in carrier matrixes
PCT/SE1999/000583 WO1999052507A1 (en) 1998-04-14 1999-04-09 Incorporation of active substances in carrier matrixes

Publications (1)

Publication Number Publication Date
EE200000595A true EE200000595A (et) 2002-04-15

Family

ID=20410946

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000595A EE200000595A (et) 1998-04-14 1999-04-09 Toimeaine viimine kandjamaatriksisse

Country Status (31)

Country Link
US (1) US6372260B1 (pt)
EP (1) EP1069890B1 (pt)
JP (1) JP2002511400A (pt)
KR (1) KR100600691B1 (pt)
CN (1) CN1201728C (pt)
AR (1) AR019262A1 (pt)
AT (1) ATE329580T1 (pt)
AU (1) AU744874B2 (pt)
BR (1) BR9909636A (pt)
CA (1) CA2327522C (pt)
CY (1) CY1105154T1 (pt)
CZ (1) CZ20003784A3 (pt)
DE (1) DE69931904T2 (pt)
DK (1) DK1069890T3 (pt)
EE (1) EE200000595A (pt)
ES (1) ES2267268T3 (pt)
HU (1) HUP0102305A3 (pt)
ID (1) ID29286A (pt)
IL (1) IL138635A0 (pt)
IS (1) IS5656A (pt)
NO (1) NO329145B1 (pt)
NZ (1) NZ507190A (pt)
PL (1) PL344077A1 (pt)
PT (1) PT1069890E (pt)
RU (1) RU2208435C2 (pt)
SE (1) SE9801287D0 (pt)
SK (1) SK14112000A3 (pt)
TR (1) TR200002960T2 (pt)
TW (1) TW542724B (pt)
WO (1) WO1999052507A1 (pt)
ZA (1) ZA992549B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
FR2824754B1 (fr) * 2001-05-15 2004-05-28 Separex Sa Procede d'obtention de particules solides a partir d'au moins un produit hydrosoluble
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
PT1429802E (pt) * 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7455797B2 (en) * 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
ES2312996T3 (es) * 2003-04-29 2009-03-01 N.V. Organon Proceso de solidificacion con antidisolvente.
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
GB2401547B (en) 2003-05-08 2005-07-20 Nektar Therapeutics Uk Ltd Particulate materials
WO2005022603A2 (en) * 2003-09-02 2005-03-10 Integral Technologies, Inc. Low cost conductive containers manufactured from conductive loaded resin-based materials
GB0602637D0 (en) 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
US20080095856A1 (en) * 2006-05-12 2008-04-24 Jacobson Gunilla B Encapsulated Nanoparticles for Drug Delivery
FR2900845B1 (fr) * 2006-05-15 2009-03-06 Commissariat Energie Atomique Procede et dispositif de synthese de particules organiques ou inorganiques enrobees
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
US7745566B2 (en) * 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
US20080260852A1 (en) * 2007-01-23 2008-10-23 Ferro Pfanstiehl Laboratories, Inc. Supercritical fluid extraction produced by in-line homogenization
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
KR102170146B1 (ko) * 2019-03-05 2020-10-26 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation

Also Published As

Publication number Publication date
CZ20003784A3 (cs) 2001-08-15
AU4066399A (en) 1999-11-01
HUP0102305A3 (en) 2003-04-28
CN1201728C (zh) 2005-05-18
PT1069890E (pt) 2006-09-29
BR9909636A (pt) 2000-12-19
CY1105154T1 (el) 2010-03-03
HUP0102305A2 (hu) 2001-12-28
DE69931904D1 (de) 2006-07-27
EP1069890B1 (en) 2006-06-14
RU2208435C2 (ru) 2003-07-20
CN1309555A (zh) 2001-08-22
IS5656A (is) 2000-10-11
ES2267268T3 (es) 2007-03-01
JP2002511400A (ja) 2002-04-16
PL344077A1 (en) 2001-09-24
SE9801287D0 (sv) 1998-04-14
NO20005150L (no) 2000-12-08
DE69931904T2 (de) 2006-12-21
NZ507190A (en) 2002-02-01
KR100600691B1 (ko) 2006-07-19
NO329145B1 (no) 2010-08-30
TW542724B (en) 2003-07-21
WO1999052507A1 (en) 1999-10-21
ATE329580T1 (de) 2006-07-15
KR20010042660A (ko) 2001-05-25
ID29286A (id) 2001-08-16
DK1069890T3 (da) 2006-08-28
AR019262A1 (es) 2002-02-13
IL138635A0 (en) 2001-10-31
TR200002960T2 (tr) 2000-12-21
CA2327522A1 (en) 1999-10-21
ZA992549B (en) 1999-10-14
US6372260B1 (en) 2002-04-16
EP1069890A1 (en) 2001-01-24
AU744874B2 (en) 2002-03-07
CA2327522C (en) 2008-03-25
SK14112000A3 (sk) 2001-07-10
NO20005150D0 (no) 2000-10-13

Similar Documents

Publication Publication Date Title
EE200000595A (et) Toimeaine viimine kandjamaatriksisse
ID22878A (id) Komposisi aktif secara terapi
NO981638D0 (no) Legemiddel- avgivelsesanordning for to eller flere aktive forbindelser
DE69821940D1 (de) Landwirtschaftlich aktive inhaltsstoffe enthaltende mikropartikel
DE69819481D1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
EE200000484A (et) Täiustused ravimi väljastusseadmetele
DE69928085D1 (de) Dosierungsform mit verlängerter wirkstoffabgabe
PT1006792E (pt) Formulacao agroquimica
PT1220856E (pt) Compostos farmaceuticamente activos
EE200000438A (et) Farmatseutiliselt aktiivne morfolinool
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
ITMI981774A0 (it) Composizioni farmaceutiche ad attivita' analgesica
DE60031633D1 (de) Wirkstofffreisetzendes elastisches band
DE69813602D1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
NO20020793D0 (no) Virkestoffkombinasjon med clonidin
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE69919490D1 (de) Puder mit fettlöslichem wirkstoff
ID24677A (id) Kombinasi senyawa aktif fungisidal
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
ITMI991766A0 (it) Fenilpirazoli ad attivita' erbicida
NO20016147D0 (no) Biologiske aktive materialer
ID23928A (id) Formulasi mengandung insektisida
DE59902159D1 (de) Aktiver mikromischer
DE69829236D1 (de) Zusammensetzungen enthaltendes biologisch aktives Silizium